journal
MENU ▼
Read by QxMD icon Read
search

Immunotherapy

journal
https://www.readbyqxmd.com/read/29043892/tofacitinib-in-the-treatment-of-active-rheumatoid-arthritis-in-adults
#1
Roy Fleischmann
Tofacitinib, a pan Janus kinase inhibitor, has been investigated as monotherapy in patients naive to methotrexate and in methotrexate incomplete responders and in combination with disease-modifying antirheumatic drugs in antirheumatic drug incomplete responders and TNF inhibitor failures in the Phase II and III programs. The clinical trial program demonstrated efficacy and a reasonable safety profile in these disease populations that has led to the approval of tofacitinib 5 mg twice daily orally in many countries...
October 18, 2017: Immunotherapy
https://www.readbyqxmd.com/read/29043884/guselkumab-for-psoriasis-a-critical-appraisal-of-phase-iii-studies
#2
Zenas Zn Yiu, Richard B Warren
Biologic therapies have raised the frontiers of accepted treatment efficacy for severe psoriasis. Guselkumab is an IgG1 monoclonal antibody that binds to the p19 subunit and inhibits IL-23. In three Phase III randomized, active comparator and placebo controlled trials, guselkumab demonstrated superior efficacy and a comparable safety profile when assessed against adalimumab and ustekinumab. Critical appraisal highlighted uncertainties over risk of bias from missing details in the trial publications that would be overcome with the provision of accompanying trial protocols, as well as the need for a head-to-head trial against an IL-17 inhibitor...
October 18, 2017: Immunotherapy
https://www.readbyqxmd.com/read/29043871/a-review-of-sarilumab-for-the-treatment-of-rheumatoid-arthritis
#3
Eun Bong Lee
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease predominantly affecting the peripheral diarthrodial joints. Sarilumab is a human monoclonal antibody against the IL-6 receptor-α. In Phase II and III clinical trials, sarilumab in the background of methotrexate showed superior clinical efficacy over placebo in RA patients with inadequate response to methotrexate or inadequate response or intolerance to TNF inhibitors. Sarilumab monotherapy also showed superior efficacy compared with adalimumab monotherapy in RA patients with inadequate response or intolerance to methotrexate...
October 18, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28967798/tofacitinib-in-psoriatic-arthritis
#4
Ting-Shun Wang, Tsen-Fang Tsai
Psoriatic arthritis is a heterogeneous disease that has been difficult to manage until the recent advent of biologics. However, there are still unmet medical needs for newer agents. Tofacitinib is a Janus family of kinases inhibitor approved for treating rheumatoid arthritis in many countries and psoriasis in Russia. We reviewed the evidences of tofacitinib in psoriatic arthritis treatment. The efficacy and safety profiles result from Phase III clinical trials (OPAL BROADEN and OPAL BEYOND) and one open-label extension study (OPAL BALANCE)...
October 2, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28967793/fostamatinib-for-persistent-chronic-adult-immune-thrombocytopenia
#5
Adrian Newland, Eun-Ju Lee, Vickie McDonald, James B Bussel
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by phagocytosis and destruction of autoantibody-coated platelets via spleen tyrosine kinase (Syk)-mediated signal transduction in macrophages. Effectiveness of existing therapies varies, and even leading treatments (e.g., IVIg, splenectomy, rituximab, thrombopoietic agents) do not provide optimal management for a substantial number of patients with chronic ITP. Fostamatinib disodium is an orally-bioavailable investigational agent being developed for treatment of primary persistent/chronic adult ITP...
October 2, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28879789/a-review-article-on-brodalumab-in-the-treatment-of-moderate-to-severe-plaque-psoriasis
#6
Omid Roostaeyan, Dario Kivelevitch, Alan Menter
Psoriasis is a chronic immune-mediated skin disorder affecting approximately 2-3% of the worldwide population. Recent advances in our understanding of the immunopathogenesis of psoriasis have resulted in novel therapeutic agents. IL-17, a pro-inflammatory cytokine, plays a pivotal role in psoriasis. Therapeutic agents targeting this cytokine have shown clinical effectiveness in the treatment of moderate-to-severe plaque psoriasis. Brodalumab, a human antibody against IL-17 receptor A, has been approved by the US FDA in February 2017, by the Japanese Pharmaceuticals and Medical Devices Agency in July 2016 and by the EMA in July 2017 for the treatment of moderate-to-severe psoriasis...
September 7, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28871852/recombinant-human-hyaluronidase-facilitated-subcutaneous-immunoglobulin-infusion-in-primary-immunodeficiency-diseases
#7
Richard L Wasserman
Most primary immunodeficiency diseases (PIDDs) resulting in antibody deficiency require intravenous or subcutaneous immunoglobulin G (SCIG) replacement therapy. The flow and distribution of SCIG to the vasculature is impeded by the glycosaminoglycan hyaluronan in the extracellular matrix, which limits the infusion rate and volume per site, necessitating frequent infusions and multiple infusion sites. Hyaluronidase depolymerizes hyaluronan and is a spreading factor for injectable biologics. Recombinant human hyaluronidase (rHuPH20) increases SCIG absorption and dispersion...
September 5, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28838285/a-review-on-golimumab-in-the-treatment-of-psoriatic-arthritis
#8
Maria Urdaneta, Hannah Jethwa, Reshma Sultan, Sonya Abraham
Psoriatic arthritis (PsA) causes inflammation in and around the joints and usually affects people who already have psoriasis. However, some patients develop the joint problems before the psoriasis. Currently, there are five anti-TNF-α agents licensed for use in patients with PsA: adalimumab, certolizumab pegol, etanercept, golimumab and infliximab. Golimumab, a human monoclonal antibody, has been approved by the US FDA for the treatment of PsA and is targeted against the pro-inflammatory molecule TNF-α. The Phase III GO-REVEAL study confirmed this drug was well tolerated and showed significant improvement in disease activity compared with placebo...
August 25, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28838282/a-retrospective-analysis-comparing-apceden-%C3%A2-dendritic-cell-immunotherapy-with-best-supportive-care-in-refractory-cancer
#9
Chaitanya Kumar, Sakshi Kohli, Srikanth Chiliveru, Poonamalle Parthasarathy Bapsy, Minish Jain, Venkata Sathya Suresh Attili, Jagan Mohan, Ashok K Vaid, Bandana Sharan
AIM: A retrospective survival benefit analysis of APCEDEN(®), APAC BIOTECH Pvt Ltd 69, Jacranda Marg, DLF PHASE II, Gurugram, Haryana, India, an autologous dendritic cell-based product for management of refractory solid malignancies, was performed in comparison with a control group. METHODS: Subjects (retrospective data) whose survival data, geographical region, age, gender, ECOG performance status and stage of disease that could be matched with the treatment group were considered for analysis...
August 25, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28771102/convergence-of-immunotherapy-radiotherapy-and-prostate-cancer-challenges-and-opportunities
#10
Michael Green, Felix Y Feng, Rohit Mehra, Daniel E Spratt
No abstract text is available yet for this article.
August 3, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28771101/natural-helper-cells-mediate-respiratory-syncytial-virus-induced-airway-inflammation-by-producing-type-2-cytokines-in-an-il-33-dependent-manner
#11
Xu Han, Ruonan Chai, Feifei Qi, Song Bai, Yulin Cui, Yuee Teng, Beixing Liu
AIM: Type 2 cytokine production during respiratory virus infection is considered to be linked with asthma exacerbation. As potent Th2 cytokine producers, natural helper (NH) cells play a key role in influenza virus-induced airway hyper-responsiveness. However, it is unclear whether NH cells contribute to respiratory syncytial virus (RSV)-induced airway inflammation, and how the cytokine profile in NH cells is changed during RSV infection. METHODS: BALB/c mice were infected intranasally with RSV...
August 3, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28771099/stabilizing-human-regulatory-t-cells-for-tolerance-inducing-immunotherapy
#12
Xuehui He, Hans Jpm Koenen, Jeroen Hr Slaats, Irma Joosten
Many autoimmune diseases develop as a consequence of an altered balance between autoreactive immune cells and suppressive FOXP3(+) Treg. Restoring this balance through amplification of Treg represents a promising strategy to treat disease. However, FOXP3(+) Treg might become unstable especially under certain inflammatory conditions, and might transform into proinflammatory cytokine-producing cells. The issue of heterogeneity and instability of Treg has caused considerable debate in the field and has important implications for Treg-based immunotherapy...
August 3, 2017: Immunotherapy
https://www.readbyqxmd.com/read/29032739/live-leishmania-tarentolae-secreting-hnp1-as-an-immunotherapeutic-tool-against-leishmania-infection-in-balb-c-mice
#13
Zahra Abdossamadi, Tahereh Taheri, Negar Seyed, Hossein Montakhab-Yeganeh, Farnaz Zahedifard, Yasaman Taslimi, Sima Habibzadeh, Elham Gholami, Safoora Gharibzadeh, Sima Rafati
AIM: Several disadvantages about chemotherapy for leishmaniasis has reinforced discovery of novel therapeutic agents especially immunotherapeutics. HNP1, as a member of the mammalian antimicrobial peptides family, is an attractive molecule due to its broad functional spectrum. Here, the in vivo potency of HNP1 in transgenic Leishmania tarentolae as an immunotherapy tool against Leishmania major-infected BALB/c mice was examined. METHODS & RESULTS: 3 weeks after infection with L...
October 2017: Immunotherapy
https://www.readbyqxmd.com/read/29032738/long-term-survival-in-a-patient-with-low-level-inflammatory-markers-and-liver-metastasis-converted-resectable-by-tace
#14
Malkhaz Mizandari, Natela Paksashvili, Nino Kikodze, Tamta Azrumelashvili, Ia Pantsulaia, Koba Shanava, Nona Janikashvili, Tinatin Chikovani
Case report presents the successful treatment of unresectable liver metastasis in a patient with colon cancer. A 44-year-old male underwent right hemicolectomy followed by capecitabine for a moderately differentiated adenocarcinoma of the colon. 2 years later, a liver metastatic lesion was detected and had increased in size despite chemotherapy with capecitabine plus oxaliplatin (XELOX). Curative liver resection was conducted after conversion of unresectable tumor to resectable by transarterial chemoembolization followed by chemotherapy - irinotecan with fluorouracil and folinic acid (FOLFIRI)...
October 2017: Immunotherapy
https://www.readbyqxmd.com/read/29032737/melanoma-a-prototype-of-cancer-testis-antigen-expressing-malignancies
#15
Sepideh Faramarzi, Soudeh Ghafouri-Fard
Melanoma is the first malignancy in which expression and immunogenicity of cancer-testis antigens (CTAs) have been documented. Several CTAs have been shown to be expressed in melanoma samples especially those with metastatic potential. Many of them have been shown to exert oncogenic effects through modulation of essential pathways involved in melanoma. The crucial role of CTAs in the pathogenesis of melanoma, the high prevalence of expression of CTA panels in melanoma and the presence of spontaneous as well as inducible immune responses against CTAs in melanoma patients potentiate CTAs as immunotherapeutic targets...
October 2017: Immunotherapy
https://www.readbyqxmd.com/read/29032736/coccidioidomycosis-immunoglobulin-deficiency-safety-challenges-with-car-t-cells-therapy-for-relapsed-lymphoma
#16
Umar Zahid, Al-Aman Shaukat, Nida Hassan, Faiz Anwer
Treatment of patients with relapsed or refractory lymphoma may require allogenic hematopoietic stem cell transplant (HSCT), but treatment of post-transplant relapse disease remains very challenging. Donor lymphocyte infusion and blinatumomab have been used with limited success for the treatment of relapse. Initial data on donor-derived CAR T cells has shown this modality to be safe and highly effective in various hematological malignancies. We present a case of a patient with highly refractory, transformed follicular lymphoma who failed both autologous and allogenic HSCT...
October 2017: Immunotherapy
https://www.readbyqxmd.com/read/29032735/sarcoidosis-malignancy-and-immune-checkpoint-blockade
#17
Elizabeth M Gaughan
No abstract text is available yet for this article.
October 2017: Immunotherapy
https://www.readbyqxmd.com/read/29032734/gammaplex-%C3%A2-5-and-10-in-the-treatment-of-primary-immunodeficiency-and-chronic-immune-thrombocytopenic-purpura
#18
Richard L Wasserman
Immunoglobulin G is used to both prevent infection in primary immunodeficiency diseases (PIDs) and prevent bleeding in immune thrombocytopenic purpura. Gammaplex is a highly purified human intravenous immunoglobulin G available as 5 and 10% liquid formulations. Gammaplex 5% has proven efficacy and safety in PID and immune thrombocytopenic purpura, protecting against serious acute bacterial infections and treating bleeding by improving platelet counts, respectively. The therapeutic effect of Gammaplex 10% is expected to be similar to that of Gammaplex 5% based on demonstrated bioequivalence in a bridging study in PID...
October 2017: Immunotherapy
https://www.readbyqxmd.com/read/29032733/car-t-cells-and-allogeneic-hematopoietic-stem-cell-transplantation-for-relapsed-refractory-b-cell-acute-lymphoblastic-leukemia
#19
Jun Liu, Xi Zhang, Jiang F Zhong, Cheng Zhang
Relapsed/refractory acute lymphoblastic leukemia (ALL) has a low remission rate after chemotherapy, a high relapse rate and poor long-term survival even when allogeneic hematopoietic stem cell transplantation (allo-HSCT) is performed. Chimeric antigen receptors redirected T cells (CAR-T cells) can enhance disease remission with a favorable outcome for relapsed/refractory ALL, though some cases quickly relapsed after CAR-T cell treatment. Thus, treatment with CAR-T cells followed by allo-HSCT may be the best way to treat relapsed/refractory ALL...
October 2017: Immunotherapy
https://www.readbyqxmd.com/read/28967792/abatacept-and-granulocyte-colony-stimulating-factor-in-a-patient-with-rheumatoid-arthritis-and-neutropenia
#20
Marta Priora, Simone Parisi, Marco Scarati, Richard Borrelli, Clara Lisa Peroni, Enrico Fusaro
Neutropenia in patients with inflammatory diseases increases the risk of infection due to the disease itself and the related immunosuppressive treatments. We report the case of a 54-year-old female with rheumatoid arthritis and following development of chronic neutropenia. All investigations excluded pathogenic relations with drugs and/or other clinical situations; the gravity of neutropenia required a treatment with G-CSF and the increased articular inflammatory activity justified a biologic-therapy, abatacept (CTLA4 inhibitors)...
October 2017: Immunotherapy
journal
journal
42164
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"